The vasomotor properties of isolated aortae and mesenteric arteries of insulin-resistant ob/ob and 57CBL/6J mice were compared in organ bath studies. Vessels from ob/ob mice were more sensitive to phenylephrine. Pretreatment with L-NAME caused similar leftward shifts of the phenylephrine concentration response curves in diabetic and non-diabetic vessels. The ob/ob aortae contracted in response to phenylephrine with roughly twice the force while they were not stiffer than control aortae. L-NAME caused a greater percentage increase in maximal force in the control than in the ob/ob tissue. Denudation potentiated force in the control aortae, but not in the ob/ob aortae. Endothelium-dependent relaxation in the ob/ob aortae and mesenteric arteries was impaired as manifested by a decreased sensitivity and maximal relaxation to acetylcholine, while the aortic basal eNOS mRNA levels did not differ between the two strains. In addition, ob/ob aortae were less sensitive to the nitric oxide donor sodium nitroprusside. Inhibition of endogenous prostaglandin synthesis with indomethacin (10 µM) partly normalized the contractile response of the ob/ob aortae and enhanced their endothelium-dependent relaxation. Neither blockade of endothelin-1 receptors (bosentan, 10 µM) nor PKC inhibition (calphostin, 1 µM) affected the contractile response to phenylephrine in the mouse aortae of either strain. In conclusion, vascular dysfunction in the aorta and mesenteric artery of ob/ob mice are due to increased smooth muscle contractility and impaired dilation but not to changes in elasticity of the vascular wall. Endothelium-produced prostaglandins contribute to the increased vasoconstriction.

Keywords:
Non-insulin-dependent diabetes mellitus, ob/ob mice, Vasoconstriction, Nitric oxide, Prostaglandins
1.
Osei K: Insulin resistance and systemic hypertension. Am J Cardiol 1999;84:33J–36J.
2.
Sowers JR, Melvin AL: Diabetes and cardiovascular disease. Diabetes Care 1999;22:C14–C20.
3.
Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Kucik DF, Quon MJ, Draznin B: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002;277:1794–1799.
4.
Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. Circulation 2000;101:676–681.
5.
Kahn AM, Husid A, Allen JC, Seidel CL, Song T: Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. Hypertension 1997;30:928–933.
6.
Sandu OA, Ragolia L, Begum N: Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle relaxation. Diabetes 2000;49:2178–2189.
7.
Arikawa E, Verma S, Dumont AS, McNeill JH: Chronic bosentan treatment improves renal artery vascular function in diabetes. J Hypertens 2001;19:803–812.
8.
Piercy VG, Taylor S: A comparison of spasmogenic and relaxant responses in aortae from C57/BL/KsJ diabetic mice with those from their non-diabetic littermates. Pharmacology 1998;56:267–275.
9.
Lagaud GJL, Masih-Khan E, Kai S, van Breemen C, Dubé GP: Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J Vasc Res 2001;38:578–589.
10.
Tesfamariam B, Jakubowski JA, Cohen RA: Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TXA2. Am J Physiol 1989;257:H1327–H1333.
11.
Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Piccoli A, Valentini U, Cimino A, Girelli A, Salvetti M, De Ciuceis C, Tiberio GA, Giulini SM, Sleiman I, Monteduro C, Rosei EA: Endothelial dysfunction in small resistance arteries of patients with non-insulin-dependent diabetes mellitus. J Hypertens 2001;19:913–919.
12.
De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM: Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130:963–974.
13.
Mayhan WG, Irvine SD, Sharpe GM: Constrictor response of resistance arterioles during diabetes mellitus. Diab Res Clin Pract 1999;44:147–156.
14.
Leckström A, Lundquist I, Ma Z, Westermark P: Islet amyloid polypeptide and insulin relationship in a longitudinal study of the genetically obese (ob/ob) mouse. Pancreas 1999;18:266–273.
15.
Mukherjee R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997,386:407–410.
16.
Winters B, Mo Z, Brooks-Asplund E, Kim S, Shoukas A, Li D, Nyhan D, Berkowitz DE: Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lepob) mice. J Appl Physiol 2000;89:2382–2390.
17.
Mural RJ, Adams MD, Myers EW, Smith HO, Gabor Miklos GL, Wides R, Halpern A, Li PW, Sutton GG, Nadeau J, et al: A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science 2002;296:1661–1671.
18.
Vanhoutte PM: Endothelin-1:A matter of life and breath. Nature 1994;368:693–694.
19.
Fabi F, Argiolas L, Ruvolo G, del Basso P: Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: Involvement of endothelium generated thromboxane. Br J Pharmacol 1998;124:101–110.
20.
Okon EB, Golbabaie A, Van Breemen C: In the presence of L-NAME SERCA blockade induces endothelium-dependent contraction of mouse aorta through activation of smooth muscle prostaglandin H2/thromboxane A2 receptors. Br J Pharmacol 2002;137:545–553.
21.
Liang CP, Tall AR: Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 2001;276:49066–49076.
22.
Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103:253–259.
23.
Randle PJ, Garland PB, Newsholme EA, Hales CN: The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann NY Acad Sci 1965;131:324–333.
24.
G.Boden: Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physns 1999;111:241–248.
25.
Silver DL, Jiang X, Tall AR: Increased high density lipoprotein, defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice. J Biol Chem 1999;274:4140–4146.
26.
Yen TT, Allan JA, Pearson DV, Schinitsky MR: Dissociation of obesity, hypercholesterolaemia and diabetes from atherosclerosis in ob/ob mice. Experimentia 1977;33:995–996.
27.
Oda A, Taniguchi T, Yokoyama M: Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001;47:141–150.
28.
Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, Spencer-Hansch C, Graf K, Nurnberg B, Law RE, Fleck E, Grafe M: Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension 2002;40:748–754.
29.
Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL: Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001;88:954–960.
30.
Muniyappa R, Srinivas PR, Ram JL, Walsh MF, Sowers JR: Calcium and protein kinase C mediate high-glucose-induced inhibition of inducible nitric oxide synthase in vascular smooth muscle cells. Hypertension 1998;31:289–295.
31.
Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999;48:1856–1862.
32.
Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R: Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998;47:457–463.
33.
Oyadomari S, Gotoh T, Aoyagi K, Araki E, Shichiri M, Mori M: Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide 2001;5:252–260.
34.
Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002;105:1656–1662.
35.
Hattori Y, Kawasaki H, Ave K, Kanno M: Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1991;261:H1086–H1094.
36.
Lemos VS, Cortes SF, Silva DM, Campagnole-Santos MJ, Santos RA: Angiotensin-(1–7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats. Br J Pharmacol 2002;135:1743–1748.
37.
Yashiro Y, Duling BR: Integrated Ca2+ signaling between smooth muscle and endothelium of resistance vessels. Circ Res 2000;87:1048–1054.
38.
Yang D, Feletou M, Boulanger CM, Wu HF, Levens N, Zhang JN, Vanhoutte PM: Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 2002;136:104–110.
39.
Zhao T, Tang H, Li X, Liu S, Zhang H, Liu Y: A study of color Doppler ultrasound on arteries of the extremities in patients with type 2 diabetes. Hua Xi Yi Ke Da Xue Xue Bao 1999;30:440–443.
40.
Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, Hanefeld M: Increasing intimal-medial thickness in newly detected type 2 diabetes. Diabetes Care 1999;22:333–338.
41.
Olsson U, Bondjers G, Camejo G: Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 1999;48:616–622.
42.
Balasubramanyam M, Balaji RA, Subashini B, Mohan V: Evidence for mechanistic alterations of Ca2+ homeostasis in type 2 diabetes mellitus. Int J Exp Diab Res 2001;1:275–287.
43.
J.Levy, JR Gavi, JR Sowers: Diabetes mellitus: A disease of abnormal cellular calcium metabolism? Am J Med 1994;96:260–273.
44.
Davel AP, Rossoni LV, Vassallo DV: Effects of ouabain on the pressor response to phenylephrine and on the sodium pump activity in diabetic rats. Eur J Pharmacol 2000;406:419–427.
45.
Dimitroloulou C, Han G, Miller A, Molero M, Fuchs L, White RE, Varrier GO: Potasium (BKCa) currents are reduced in microvascular smooth muscle cells from insulin-resistant rats. Am J Physiol Heart Circ Physiol 2002;282:H908–H917.
46.
Liu Y, Gutterman DD: The coronary circulation in diabetes: Influence of reactive oxygen species on K+ channel-mediated vasodilation. Vasc Pharmacol 2002;38:43–49.
47.
Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR: Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart. J Biol Chem 1997;272:23696–23702.
48.
Grover AK, Samson SE, Misquitta CM, Elmoselhi AB: Effects of peroxide on contractility of coronary artery rings of different sizes. Mol Cell Biochem 1999;194:159–164.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.